JP2020517692A - 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 - Google Patents

治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 Download PDF

Info

Publication number
JP2020517692A
JP2020517692A JP2019557872A JP2019557872A JP2020517692A JP 2020517692 A JP2020517692 A JP 2020517692A JP 2019557872 A JP2019557872 A JP 2019557872A JP 2019557872 A JP2019557872 A JP 2019557872A JP 2020517692 A JP2020517692 A JP 2020517692A
Authority
JP
Japan
Prior art keywords
cells
genetically modified
cell
subject
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019557872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517692A5 (cg-RX-API-DMAC10.html
Inventor
マシュー レイン ショルツ，
マシュー レイン ショルツ，
エリック ジェイ． ハービッグ，
エリック ジェイ． ハービッグ，
アール． スコット マカイバー，
アール． スコット マカイバー，
ラート， ライアン デ
ラート， ライアン デ
エリック オルソン，
エリック オルソン，
Original Assignee
イミュソフト コーポレーション
イミュソフト コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュソフト コーポレーション, イミュソフト コーポレーション filed Critical イミュソフト コーポレーション
Publication of JP2020517692A publication Critical patent/JP2020517692A/ja
Publication of JP2020517692A5 publication Critical patent/JP2020517692A5/ja
Priority to JP2023072284A priority Critical patent/JP7526312B2/ja
Priority to JP2024115656A priority patent/JP2024153703A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2019557872A 2017-04-27 2018-04-27 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量 Withdrawn JP2020517692A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023072284A JP7526312B2 (ja) 2017-04-27 2023-04-26 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量
JP2024115656A JP2024153703A (ja) 2017-04-27 2024-07-19 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762491151P 2017-04-27 2017-04-27
US62/491,151 2017-04-27
PCT/US2018/029993 WO2018201071A1 (en) 2017-04-27 2018-04-27 B cells for in vivo delivery of therapeutic agents and dosages thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023072284A Division JP7526312B2 (ja) 2017-04-27 2023-04-26 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量

Publications (2)

Publication Number Publication Date
JP2020517692A true JP2020517692A (ja) 2020-06-18
JP2020517692A5 JP2020517692A5 (cg-RX-API-DMAC10.html) 2021-05-20

Family

ID=63919297

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019557872A Withdrawn JP2020517692A (ja) 2017-04-27 2018-04-27 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量
JP2023072284A Active JP7526312B2 (ja) 2017-04-27 2023-04-26 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量
JP2024115656A Pending JP2024153703A (ja) 2017-04-27 2024-07-19 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023072284A Active JP7526312B2 (ja) 2017-04-27 2023-04-26 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量
JP2024115656A Pending JP2024153703A (ja) 2017-04-27 2024-07-19 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量

Country Status (8)

Country Link
US (1) US20220193129A1 (cg-RX-API-DMAC10.html)
EP (1) EP3615045A4 (cg-RX-API-DMAC10.html)
JP (3) JP2020517692A (cg-RX-API-DMAC10.html)
CN (1) CN110709090A (cg-RX-API-DMAC10.html)
AU (2) AU2018256887B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019022473A2 (cg-RX-API-DMAC10.html)
CA (1) CA3061048A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018201071A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548118A (ja) * 2020-10-30 2023-11-15 イミュソフト コーポレーション 治療剤のｉｎ ｖｉｖｏ送達のために、遺伝子改変Ｂ細胞を投与する方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
US12440513B2 (en) 2019-03-22 2025-10-14 Albany Medical College Methods for improving cognitive function
CN110499336B (zh) * 2019-08-23 2021-10-12 华南农业大学 一种利用小分子化合物提高基因组定点修饰效率的方法
WO2021108650A1 (en) * 2019-11-27 2021-06-03 Board Of Regents, The University Of Texas System Large-scale combined car transduction and crispr gene editing of b cells
KR20240024781A (ko) * 2021-04-19 2024-02-26 워킹 피쉬 테라퓨틱스 인코포레이티드 세포 요법에 사용하기 위한 b 세포 확장의 방법
TW202423959A (zh) * 2022-08-24 2024-06-16 美商步行魚醫療公司 用於治療法布瑞氏症(fabry disease)之組成物及方法
WO2024220447A2 (en) * 2023-04-17 2024-10-24 Be Biopharma, Inc. Engineered cell preparations for treatment of niemann pick b disease
KR20250175332A (ko) * 2023-04-17 2025-12-16 비이 바이오파마, 인크. 혈우병 치료를 위한 조작된 세포 제제
US20250152714A1 (en) 2023-11-15 2025-05-15 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy
WO2026085108A2 (en) 2024-10-14 2026-04-23 Immusoft Corporation B cell compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527051A (ja) * 2006-04-27 2008-07-24 ソウル ナショナル ユニバーシティー インダストリー ファウンデーション ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン
WO2016100932A1 (en) * 2014-12-19 2016-06-23 Immusoft Corporation B cells for in vivo delivery of therapeutic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016202625A1 (en) * 2007-07-27 2016-05-19 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
DK2521789T3 (en) * 2010-01-08 2017-03-27 Immusoft Corp VECTORS AND PROCEDURE FOR B-CELL TRANSDUCTION
ES2786253T3 (es) * 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
ES2749862T3 (es) * 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
KR20220082100A (ko) * 2015-05-15 2022-06-16 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 치료적 전달
CA3093716A1 (en) * 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527051A (ja) * 2006-04-27 2008-07-24 ソウル ナショナル ユニバーシティー インダストリー ファウンデーション ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン
WO2016100932A1 (en) * 2014-12-19 2016-06-23 Immusoft Corporation B cells for in vivo delivery of therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOTARGET, vol. 7, no. 29, JPN6022012747, 2016, pages 46173 - 46186, ISSN: 0004739702 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023548118A (ja) * 2020-10-30 2023-11-15 イミュソフト コーポレーション 治療剤のｉｎ ｖｉｖｏ送達のために、遺伝子改変Ｂ細胞を投与する方法

Also Published As

Publication number Publication date
WO2018201071A1 (en) 2018-11-01
AU2018256887A1 (en) 2019-11-07
AU2025202508A1 (en) 2025-06-05
JP2023093703A (ja) 2023-07-04
CA3061048A1 (en) 2018-11-01
CN110709090A (zh) 2020-01-17
RU2019136194A (ru) 2021-05-27
JP2024153703A (ja) 2024-10-29
EP3615045A1 (en) 2020-03-04
NZ758331A (en) 2025-12-19
US20220193129A1 (en) 2022-06-23
JP7526312B2 (ja) 2024-07-31
EP3615045A4 (en) 2021-01-13
BR112019022473A2 (pt) 2020-10-20
AU2018256887B2 (en) 2025-01-09
RU2019136194A3 (cg-RX-API-DMAC10.html) 2021-08-02

Similar Documents

Publication Publication Date Title
JP7526312B2 (ja) 治療剤のｉｎ ｖｉｖｏ送達のためのＢ細胞およびその投薬量
US20230081163A1 (en) B cells for in vivo delivery of therapeutic agents
JP6689897B2 (ja) インビトロでのメモリーｂ細胞分化方法およびｖｓｖ−ｇ偽型ウイルスベクターを用いる形質導入方法
JP5873807B2 (ja) Ｂ細胞を形質導入するためのベクターおよび方法
AU2019233929B2 (en) B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
US20230414659A1 (en) Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
RU2812477C2 (ru) В-клетки для доставки терапевтических средств in vivo и их дозы
RU2832170C2 (ru) B-клетки, генетически модифицированные для секреции фоллистатина, и способы их применения для лечения связанных с фоллистатином заболеваний, состояний, нарушений и для увеличения роста и силы мышц
CA2971430C (en) B cells for in vivo delivery of therapeutic agents
HK40040375A (en) B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
HK1245834B (en) B cells for in vivo delivery of therapeutic agents
HK1178934A (en) Vectors and methods for transducing b cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230426

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230509

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230512